🇺🇸 FDA
Pipeline program

GWP42006

GWND18089

Phase 2 small_molecule terminated

Quick answer

GWP42006 for Autism Spectrum Disorder is a Phase 2 program (small_molecule) at Jazz Pharmaceuticals plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Jazz Pharmaceuticals plc
Indication
Autism Spectrum Disorder
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials